South Korea · Delayed Price · Currency is KRW Chabiotech Statistics
Total Valuation
Chabiotech has a market cap or net worth of KRW 1.14 trillion. The enterprise value is 2.16 trillion.
| Market Cap | 1.14T |
| Enterprise Value | 2.16T |
Important Dates
The last earnings date was Thursday, May 28, 2026.
| Earnings Date | May 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Chabiotech has 92.50 million shares outstanding. The number of shares has increased by 137.28% in one year.
| Current Share Class | 92.50M |
| Shares Outstanding | 92.50M |
| Shares Change (YoY) | +137.28% |
| Shares Change (QoQ) | +36.28% |
| Owned by Insiders (%) | 14.56% |
| Owned by Institutions (%) | 16.88% |
| Float | 69.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.88 |
| PB Ratio | 1.12 |
| P/TBV Ratio | 3.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -29.39 |
| EV / Sales | 1.67 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -7.59 |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 0.94.
| Current Ratio | 0.88 |
| Quick Ratio | 0.78 |
| Debt / Equity | 0.94 |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.35 |
| Interest Coverage | -1.37 |
Financial Efficiency
Return on equity (ROE) is -14.09% and return on invested capital (ROIC) is -5.11%.
| Return on Equity (ROE) | -14.09% |
| Return on Assets (ROA) | -1.89% |
| Return on Invested Capital (ROIC) | -5.11% |
| Return on Capital Employed (ROCE) | -4.66% |
| Weighted Average Cost of Capital (WACC) | 5.97% |
| Revenue Per Employee | 4.65B |
| Profits Per Employee | -264.22M |
| Employee Count | 278 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 17.73 |
Taxes
In the past 12 months, Chabiotech has paid 3.13 billion in taxes.
| Income Tax | 3.13B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +22.98% in the last 52 weeks. The beta is 0.53, so Chabiotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | +22.98% |
| 50-Day Moving Average | 16,376.40 |
| 200-Day Moving Average | 14,989.20 |
| Relative Strength Index (RSI) | 23.92 |
| Average Volume (20 Days) | 439,202 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Chabiotech had revenue of KRW 1.29 trillion and -73.45 billion in losses. Loss per share was -976.81.
| Revenue | 1.29T |
| Gross Profit | 357.54B |
| Operating Income | -75.12B |
| Pretax Income | -119.22B |
| Net Income | -73.45B |
| EBITDA | -17.99B |
| EBIT | -75.12B |
| Loss Per Share | -976.81 |
Balance Sheet
The company has 435.81 billion in cash and 952.32 billion in debt, with a net cash position of -516.50 billion or -5,583.85 per share.
| Cash & Cash Equivalents | 435.81B |
| Total Debt | 952.32B |
| Net Cash | -516.50B |
| Net Cash Per Share | -5,583.85 |
| Equity (Book Value) | 1.02T |
| Book Value Per Share | 5,801.60 |
| Working Capital | -139.83B |
Cash Flow
In the last 12 months, operating cash flow was -102.92 billion and capital expenditures -181.63 billion, giving a free cash flow of -284.55 billion.
| Operating Cash Flow | -102.92B |
| Capital Expenditures | -181.63B |
| Depreciation & Amortization | 57.13B |
| Net Borrowing | 85.48B |
| Free Cash Flow | -284.55B |
| FCF Per Share | -3,076.25 |
Margins
Gross margin is 27.63%, with operating and profit margins of -5.81% and -5.68%.
| Gross Margin | 27.63% |
| Operating Margin | -5.81% |
| Pretax Margin | -9.21% |
| Profit Margin | -5.68% |
| EBITDA Margin | -1.39% |
| EBIT Margin | -5.81% |
| FCF Margin | n/a |
Dividends & Yields
Chabiotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -137.28% |
| Shareholder Yield | -137.28% |
| Earnings Yield | -6.45% |
| FCF Yield | -24.99% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 2, 2014. It was a reverse split with a ratio of 0.7262.
| Last Split Date | Jun 2, 2014 |
| Split Type | Reverse |
| Split Ratio | 0.7262 |
Scores
Chabiotech has an Altman Z-Score of 0.75 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.75 |
| Piotroski F-Score | 2 |